Advances on non-invasive physically triggered nucleic acid delivery from nanocarriers
Graphical abstract
Introduction
Nucleic acids (NAs) are among the most important biomolecules. Their main function is to store and to transfer genetic information. Although being discovered very early in 1869, researches involving in NAs have achieved amazing progress in the past few decades. In medicine, NAs are considered as promising therapeutic agents for various types of diseases, from hereditary diseases to acquired diseases such as cancer, degenerative disorders and AIDS. Therapeutic NAs can be categorized into DNA therapeutics (antisense oligonucleotides, DNA aptamers and gene therapy) and RNA therapeutics (micro RNAs (miRNA), short interfering RNAs (siRNA), ribozymes, RNA decoys and circular RNAs) [1]. Since the first successful and accepted nuclear gene transfer in humans in May 1989, a lot of nucleic acid-based treatments have been fabricated and taken into clinical trials [2]. In 2012, Glybera®, an adeno- associated viral vector engineered to express lipoprotein lipase for the treatment of lipoprotein lipase deficiency, was approved as the first gene therapy treatment for sale in the European Union [3]. Until 2016, there are approximately 2600 gene therapies clinical trials [2] and about 20 clinical trials using miRNA and siRNA-based therapies [4]. Moreover, in 2016, the first ex-vivo stem cell gene therapy, Strimvelis™, was accepted in Europe for Severe Combined ImmunoDeficiency due to Adenosine DeAminase deficiency treatment [5].
Efficient cell delivery of NAs is hampered by their charge, high molecular weight and instability in biological environment. Many strategies have been proposed to obtain effective gene delivery to targeted cells [5]. An effective gene delivery system should have the following properties: (i) be able to carry and to protect the therapeutic genes; (ii) accumulate at targeted tissues, and (iii) release the entrapped payload at the targeted tissue. There are two kinds of vector for gene delivery: viral and non-viral vectors. Viral vectors are outstanding candidates for gene delivery due to their high transfection efficiency and ability to incorporate the delivered gene into the host genome [6]. Although serious side-effects of viral vectors leading to patient death and lymphoproliferative disorder were encountered [7], after numerous modifications and innovations, many viral vectors with improved efficiency, specificity and safety have been developed and transferred into clinical trials. Today, viral vectors are used in approximately two thirds of gene therapy trials performed [2]. However, there are still some drawbacks in the use of viral vectors such as: the complexity and high cost of production, and the limited size of transgene inserted in viral vectors [8]. Meanwhile, non-viral vectors are highly interesting delivery systems due to their large versatility: they can be composed of organic materials (for example: polymers, liposomes, peptides…), carbon nanotubes, or inorganic nanoparticles (such as gold NPs, magnetic NPs (MNPs)…) [6]. They can be designed to transfer different and large transgenes [8].
After administration, non-viral vectors are usually uptaken by the cells through endosomal pathway. Because of harsh environment inside endosome (low pH, digestive enzymes), NAs risk to be degraded before reaching their site of action. Endosomal escape and triggered release of the entrapped gene at the target site, therefore, are important requirements for an effective NA-based treatment. For that reason, stimuli-responsive gene delivery systems are under evaluation. Stimuli-responsive vectors should hold off the release function while they are in the blood stream and release entrapped genes inside the cells under exposure to stimuli source which can be internal or external triggers. Internal triggers are based on abnormalities of pathological area such as different pH, redox potential, temperature and over expression of some molecules like enzymes. For instance, in breast and pancreatic cancers, there is a significant increase in the expression of phospholipase A2, or in inflammatory area, there are some soluble extracellular enzymes such as lysozyme, cathepsins and matrix metalloproteinases [9]. A metalloproteinase 2 responsive block copolymer composed of poly(ethylene glycol) (PEG), matrix metalloproteinase 2 (MMP-2)-degradable peptide PLG*LAG, cationic cell penetrating peptide polyarginine r9 and poly(ε-caprolactone) (PCL) was employed for siRNA against polo-lie kinase 1 (Plk1) delivery. The micelle carrying siRNA showed enhanced gene silencing and tumor growth inhibition. About 49% of cells treated with metalloproteinase responsive siRNA delivery system underwent apoptosis while cells treated with unresponsive system presented only about 24% of death. Furthermore, Plk1 mRNA levels was significantly lower in mice treated with responsive system compared to that with unresponsive system (p < 0.005) [10]. Beside, due to hypoxia, pH may drop to around 6 in the tumor area [11] or inflammation tissues [12]. Taking advantage of this difference, Du et al. designed nanomicelle system based on poly(ethylene glycol)-co-poly[(2, 4, 6-trimethoxybenzylidene-1, 1, 1-tris(hydroxymethyl)] ethane methacrylate-co-poly(dimethylamino glycidyl methacrylate) PEG-PTTMA-P(GMA-S-DMA) (PTMS) for pH responsive siRNA release strategy. In acidic environment, PTTMA polymers undergoes hydrophobic-to-hydrophilic transition leading to the disassembly of the nanomicelle and therefore the siRNA release. Results from in vitro experiments showed that in cells treated with PTMS nanomicelle-based siRNA delivery system there was a highly efficient gene silencing of about 90%, which was even better than that with Lipofectamine 2000. This result was also confirmed through in vivo studies: in mice group treated with PTMS/siRNA complex, tumor growth was significantly inhibited and about 45% gene knockdown efficacy was observed. This enhancing gene silencing effect was attributed to the enhanced siRNA endosomal release [13]. In addition, in cancer cells, the level of glutathione is found to be 100-fold higher than the normal ranges [14]. Glutathione, therefore, can be used as a trigger for stimulus NA release. For example, a DNA delivery nanocarrier called Pluronic-PEI-SS synthesized by conjugating reducible disulfide-linked PEI (PEI-SS) with Pluronic was fabricated. The disulfide link is broken under the action of glutathione. The Pluronic-PEI-SS system showed the highest DNA transfection efficacy into cells of about 4, 3 and 13 times higher than that of Pluronic-PEI, PEI-SS and PEI systems, respectively. Moreover, in vivo experiment, the Pluronic-PEI-SS nanocarrier also exhibited a significantly higher transfection efficacy than the PEI/DNA [15]. Numerous other efforts have been carried out to prompt the release of entrapped gene by internal triggers with promising results and have been recently summarized in many reviews [12,14,16].
However, triggered gene release by intrinsic physical and biological factors faces many limitations. The environment of the disease site is heterogeneous and strongly depends on patient's conditions such as illness or diet, therefore the effects are not easy to predict. In addition, after administration, it is impossible to control or modify the action of the gene delivery systems. Compared to endogenous triggers, exogenous triggered gene release is time and site specifically controllable through active management of external stimuli. Non-invasive external signal like light, heat, magnetic field or ultrasound is applied to the target site from an outside source. The signal induces changes in the stability of the delivery system or some specific reactions which lead to endosomal escape and gene release.
In this review, we will go into details of some external trigger strategies for gene delivery, including ultrasound, magnetic field, light and temperature. In each strategy, mechanism of action and examples are covered. Furthermore, challenges and perspectives of these kinds of smart-gene delivery systems are also discussed.
Section snippets
Ultrasound triggered release
Ultrasound can be defined as pressure waves through a medium, these ultrasonic signals can be reflected, deviated and absorbed according to the environment [17]. More specifically, it generates three main effects, hyperthermia, acoustic pressure and cavitation (Fig. 1) leading to molecules motion as the medium is compressed and decompressed throughout the experimentation.
Consequently, ultrasound fosters blood vessels permeability and cellular uptake of drugs, as it leads to mechanical flows and
Magnetically triggered release
Magnetic field is considered as one of the best triggering strategies for an externally responsive drug/gene release from drug delivery systems. Contrary to light which meets limitation of non-invasive application for deep tissue, magnetic fields are able to deeply penetrate into the whole body. The penetration depth depends on wavelength and decreases by increasing the frequency. It drops from 17 cm at 85 MHz to 7 cm at 220 MHz [65]. On the other hand, magnetic field seems to be safer thanks
Light triggered release
Photo-responsive release is a very popular on-demand gene release strategy thanks to its non-invasive property and ability to precisely control with regard to location, dose and time at which therapeutic genes are released.
Light spectrum used to trigger gene release ranges from ultraviolet (UV) (10–400 nm) to near infrared (NIR) regions (650–900 nm). Nevertheless, UV irradiation is more cytotoxic than other regions and can be absorbed by endogenous chromophores (such as hemoglobin, lipids and
Hypothermia triggered release
As mentioned in Part 3 and Part 4, thermosensitive materials can be used for remote-triggered release of NA. Besides release by hyperthermia, gene release by hypothermia can be developed based on a treatment called “cold-shock” (Fig. 4). In this strategy, thermosensitive polymers with LCST of lower than body temperature are employed. At temperature above LCST, they are collapsed so they form dense NPs which can encapsulate or complex with NA. When the temperature is reduced to lower than LCST,
Conclusion, challenges and perspectives
Mild Hyperthermia or therapeutic hyperthermia (40–42 °C) is already used in clinic to treat cancer, in particular peritoneal metastases using heated perfused chemotherapy, or hepatic metastases using radiofrequency. Combination therapy of hyperthermia with radiation therapy is currently being investigated in a phase I/II for soft tissue carcinoma of the limbs with a compatible magnetic field.
Magnetic resonance-guided focused ultrasound (MRg-FU) is also being investigated for the thermal
Conflict of interest
The authors declare no conflict of interest in the publication of this work.
Acknowledgement
This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 665850.
References (129)
Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European union
Mol. Ther.
(2012)- et al.
Therapeutic miRNA and siRNA: moving from Bench to Clinic as Next Generation Medicine
Mol. Ther. - Nucleic Acids.
(2017) - et al.
Gene therapy and DNA delivery systems
Int. J. Pharm.
(2014) - et al.
Matrix metalloproteinase 2-responsive micelle for siRNA delivery
Biomaterials
(2014) - et al.
The relevance of tumor pH to the treatment of malignant disease
Radiother. Oncol.
(1984) - et al.
Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications
Adv. Drug Deliv. Rev.
(2012) - et al.
Cavitation-enhanced extravasation for drug delivery
Ultrasound Med. Biol.
(2011) - et al.
Sonoporation using microbubble BR14 promotes pDNA/siRNA transduction to murine heart
Biochem. Biophys. Res. Commun.
(2005) - et al.
Cationic microbubbles and antibiotic-free miniplasmid for sustained ultrasound–mediated transgene expression in liver
J. Control. Release
(2017) - et al.
Mechanical and biological effects of ultrasound: a review of present knowledge
Ultrasound Med. Biol.
(2017)
Ultrasound-sensitive siRNA-loaded nanobubbles formed by hetero-assembly of polymeric micelles and liposomes and their therapeutic effect in gliomas
Biomaterials
Ultrasound assisted siRNA delivery using PEG-siPlex loaded microbubbles
J. Control. Release
Local delivery of E2F decoy oligodeoxynucleotides using ultrasound with microbubble agent (Optison) inhibits intimal hyperplasia after balloon injury in rat carotid artery model
Biochem. Biophys. Res. Commun.
Ultrasound-targeted antisense oligonucleotide attenuates ischemia/reperfusion-induced myocardial tumor necrosis factor-alpha
J. Mol. Cell. Cardiol.
Sonoporation Using Microbubble BR14 Promotes pDNA/siRNA Transduction to Murine heart
Myocardium-targeted delivery of endothelial progenitor cells by ultrasound-mediated microbubble destruction improves cardiac function via an angiogenic response
J. Mol. Cell. Cardiol.
Ultrasound Assisted Gene and Photodynamic Synergistic Therapy with Multifunctional FOXA1-siRNA Loaded Porphyrin Microbubbles for Enhancing Therapeutic Efficacy for Breast Cancer
Kidney-specific sonoporation-mediated gene transfer
Mol. Ther.
Sonoporation-mediated transduction of siRNA ameliorated experimental arthritis using 3 MHz pulsed ultrasound
Ultrasonics
Optimization of ultrasound parameters for cardiac gene delivery of adenoviral or plasmid deoxyribonucleic acid by ultrasound-targeted microbubble destruction
J. Am. Coll. Cardiol.
Ultrasound-mediated transfection of canine myocardium by intravenous administration of cationic microbubble-linked plasmid DNA
J. Am. Soc. Echocardiogr.
Targeted tissue transfection with ultrasound destruction of plasmid-bearing cationic microbubbles
Ultrasound Med. Biol.
Ultrasound-mediated microbubble destruction enhances VEGF gene delivery to the infarcted myocardium in rats
Clin. Imaging
Ultrasound-enhanced siRNA delivery using magnetic nanoparticle-loaded chitosan-deoxycholic acid nanodroplets
Adv. Healthc. Mater.
Delivery of siRNA into the cytoplasm by liposomal bubbles and ultrasound
J. Control. Release
Thermal and magnetic dual-responsive liposomes with a cell-penetrating peptide-siRNA conjugate for enhanced and targeted cancer therapy
Colloids Surfaces B Biointerfaces.
Microcapsules of alginate/chitosan containing magnetic nanoparticles for controlled release of insulin
Colloids Surfaces B Biointerfaces.
Local hyperthermia treatment of tumors induces CD8+T cell-mediated resistance against distal and secondary tumors
Nanomed. Nanotechnol.
Stimuli responsive charge-switchable lipids: Capture and release of nucleic acids
Chem. Phys. Lipids
Photo-tearable tape close-wrapped upconversion nanocapsules for near-infrared modulated efficient siRNA delivery and therapy
Biomaterials
Therapeutic nucleic acids: current clinical status
Br. J. Clin. Pharmacol.
Gene therapy clinical trials worldwide to 2017 - an update
J. Gene Med.
Gene therapy 2017: Progress and future directions
Clin. Transl. Sci.
Recent advances in Nanomaterials for Gene Delivery—a Review
Nano
Progress and problems with the use of viral vectors for gene therapy
Nat. Rev. Genet.
Trigger release liposome systems: local and remote controlled delivery?
J. Microencapsul.
Advances in stimulus-responsive polymeric materials for systemic delivery of nucleic acids
Adv. Healthc. Mater.
The pH-triggered triblock nanocarrier enabled highly efficient siRNA delivery for cancer therapy
Theranostics.
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
Nat. Rev. Drug Discov.
Intracellular redox-responsive nanocarrier for plasmid delivery: in vitro characterization and in vivo studies in mice
Int. J. Nanomedicine
Ultrasonic drug delivery--a general review
Expert Opin. Drug Deliv.
Ultrasound-guided drug delivery in cancer
Ultrason. (Seoul, Korea).
The cellular and molecular basis of hyperthermia
Crit. Rev. Oncol. Hematol.
Thermally induced apoptosis, necrosis, and heat shock protein expression in 3D culture
J. Biomech. Eng.
Reduction of peak acoustic pressure and shaping of heated region by use of multifoci sonications in MR-guided high-intensity focused ultrasound mediated mild hyperthermia
Med. Phys.
Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer
Sci. Rep.
Stimuli-responsive nanoparticles for siRNA delivery
Curr. Pharm. Des.
Microbubbles and ultrasound: from diagnosis to therapy
Eur. J. Echocardiogr.
Gene transfer with echo-enhanced contrast agents: comparison between Albunex, Optison, and Levovist in mice--initial results
Radiology
Targeted delivery of biodegradable nanoparticles with ultrasound-targeted microbubble destruction-mediated hVEGF-siRNA transfection in human PC-3 cells in vitro
Int. J. Mol. Med.
Cited by (31)
Ultrasound image-guided cancer gene therapy using iRGD dual-targeted magnetic cationic microbubbles
2024, Biomedicine and PharmacotherapyEndogenous stimuli-responsive drug delivery nanoplatforms for kidney disease therapy
2023, Colloids and Surfaces B: BiointerfacesLong-term biophysical stability of nanodiamonds combined with lipid nanocarriers for non-viral gene delivery to the retina
2023, International Journal of PharmaceuticsBiomimetic gene editing system for precise tumor cell reprogramming and augmented tumor therapy
2023, Journal of Controlled ReleaseSelf-amplified ROS production from fatty acid oxidation enhanced tumor immunotherapy by atorvastatin/PD-L1 siRNA lipopeptide nanoplexes
2022, BiomaterialsCitation Excerpt :As compared to Lipo2000, FAM-siRNA@SLNP displayed a much broader distribution of green fluorescence signal of FAM siRNA and much less orange signal due to the overlap of FAM siRNA and Lysotracker red (Fig. 3c), indicating the effectively endo-lysosome escape of siRNA. Because one of the main intracellular barriers for siRNA delivery is endo-lysosomal entrapment [55–57], high efficiency of PD-L1 silencing by the lipopeptide nanoplexes also suggests the efficient endo-lysosome escape of siRNA (Fig. 3d). The mechanism of the lipopeptide facilitated endo-lysosome escape was studied by blocking the “proton sponge” effect with proton pump inhibitor and by mesuring the membrane permeability of stearyl-pArg8.